A Real-World Study: Evaluating Long-Term Mortality in Patients Treated by High-Dose PCBA vs POBA

Published: 29 Oct 2019

  • Views:

    Views Icon 126
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

Prof Konstantinos Donas (St Franziskus Hospital, DE) meets with Prof Frank Vermassen (University of Ghent, BE) and Dr Gergana Taneva (University Hospital Ramón y Cajal, ES) to discuss the latest results from his 5-year, real-world study: Evaluating long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon angioplasty (PCBA) versus plain balloon angioplasty (POBA)


Highlights of this short 10-min roundtable include; a discussion on the use of paclitaxel and its impact on mortality, an overview of the real-world study results vs related randomised control studies and the impact these have on a surgeon's daily practice, as well as a discussion around treatment strategies and the importance of further studies in this field of medicine. 


Filmed by Radcliffe Vascular during CIRSE 2019.

Videographer: Tom Brown, Dave Good